Catalyst

Slingshot members are tracking this event:

Horizon Pharma (HZNP) Down 17% After Negative NY Times Article On High Price of Arthritis Pill Duexis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
HZNP

100%

Additional Information

Media/Analyst Viewpoint The pain reliever Duexis is a combination of two old drugs, the generic equivalents of Motrin and Pepcid. If prescribed separately, the two drugs together would cost no more than $20 or $40 a month. By contrast, Duexis, which contains both in a single pill, costs about $1,500 a month. Needless to say, many insurers do not want to pay for Duexis. Yet sales of the drug are growing rapidly, in large part because its manufacturer, Horizon Pharma, has figured out a way to circumvent efforts of insurers and pharmacists to switch patients to the generic components, or even to the over-the-counter versions.
http://www.nytimes.c...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 20, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Drug Pricing, Duexis, Osteoarthritis, Motrin, Pepcid, New York Times, Famotidine, Ibuprofen